Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer

Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer

Products Related to gp41, gp120,

Product#1091 Recombinant HIV-1 MN gp41 Envelope Protein (E.coli)

Product#1001 Recombinant HIV-1 IIIB Envelope Glycoprotein gp120 (Baculovirus)


The trimeric envelope (Env) glycoprotein spike of human immunodeficiency virus type 1 (HIV-1) plays a crucial role in mediating host cell infection. Its exposed position on the virus surface also makes it the target for potent, broadly neutralizing antibodies (bNAbs) that are produced in a subset of infected individuals and that now influence the design of Env immunogens intended to induce similar antibody specificities. Env is extensively glycosylated, with glycans contributing to a significant proportion of the glycoprotein's mass (). The heavily glycosylated surface of Env has been referred to as the “silent face,” with the glycans acting to shield the underlying viral protein surface from immune surveillance (,). The glycan shield constantly evolves to protect the virus from newly produced neutralizing antibodies. However, compared to the highly diverse protein component of Env, many of the potential N-glycosylation sites (PNGSs) are well conserved; their total number has also remained relatively constant despite years of viral evolution (, ). While the glycans are derived from the host cell's glycosylation machinery, their high density leads to a large abundance of underprocessed, oligomannose-type glycans (Man5–9GlcNAc2) (,). The glycan shield is therefore surprisingly homogenous given the extent of glycosylation, and it is itself a target for bNAbs that recognize exclusively glycan or mixed glycan/protein epitopes (,).

The Env spike is a trimer of heterodimers composed of gp41 and gp120 subunits, which are generated when a protease, usually furin, cleaves the proprotein gp160 glycoprotein (,). Furin most probably cleaves gp160 in the trans-Golgi network (TGN), but it is able to cycle between the TGN, the endosomal compartments, and the cell surface and is also believed to be able to act in the early secretory pathway (, , ). Furin is an important factor in Env immunogen production, as it is now commonly coexpressed to generate fully cleaved recombinant soluble trimers that structurally mimic native Env (, ). In contrast, structural and antigenic analyses of many uncleaved Env constructs show that they adopt nonnative conformations, with gp120 subunits dangling from a gp41 core, unless additional modifications are made to overcome the defect (,). Cleavage is therefore important for the structural integrity of the trimer, which in turn greatly influences how the trimer is glycosylated (, ).

Several studies on monomeric gp120 proteins have demonstrated the presence of a cluster of oligomannose-type glycans, the “intrinsic mannose patch” (IMP), which arises because the glycan shield creates steric constraints that restrict the actions of endoplasmic reticulum (ER) and Golgi apparatus α-mannosidases (, , , ,). The IMP is localized at the outer domain of gp120 and comprises the epitopes of numerous glycan-influenced bNAbs (, , , , ,). The IMP is a characteristic feature of gp120 that is conserved across all HIV-1 clades (, , ) and longitudinally during infection (). Analyses of recombinant soluble, native-like trimers (, ), membrane-associated trimers (), and virion-derived Env (,) all show that their oligomannose-type glycan contents are even higher than those of gp120 monomers, implying that a “trimer-associated mannose patch” (TAMP) exists (). However, the glycan sites forming any such TAMP have not previously been defined.

Cleaved, soluble, native-like Env trimers are currently one focus of structure-guided immunogen design programs. A detailed site-specific N-glycosylation analysis of the prototype of this class of trimers, BG505 SOSIP.664, revealed fine structural details of the glycan shield (, , ). The gp120 subunit of this trimer is dominated by underprocessed Man8–9GlcNAc2 glycans, which form a mosaic of densely organized oligomannose clusters on the outer domain and the trimer interface (, ). In contrast, glycosylation sites with a mixed processing state (i.e., sites containing both highly processed, complex, and oligomannose-type glycans) are found at the trimer apex and near its N and C termini (). Compact folding seems to be the major driver behind the oligomannose-dominated profile of the glycan shield on native trimers. For example, uncleaved, nonnative constructs that adopt a much more open and irregular conformation have a significantly reduced content of oligomannose-type glycans, because the now more accessible structures are efficiently processed (, ). We refer here to these uncleaved, nonnative glycoproteins as pseudotrimers, to reflect their lack of the 3-fold symmetry that is a characteristic feature of the structures of natively folded trimers (, ).

Here we reveal the detailed effects of cleavage-induced, native-like trimerization on N-glycan processing. Our quantitative, site-specific analysis of a set of comparably expressed and purified monomeric (i.e., gp120), uncleaved pseudotrimeric, and fully cleaved trimeric envelope glycoproteins of the same genotype (i.e., BG505) identifies the location of the cleavage-dependent TAMP. Thus, the glycans that form the TAMP are found in regions near the trimer apex and the protomer interface. We show that compared to those in pseudotrimers, these regions are even more highly processed on monomeric gp120, implying that the oligomerization events impose additional regional restrictions on glycan processing. This finding is echoed across the panel of glycoproteins in the analysis of O-linked glycosylation at T499, near the trimer base, which is present at almost unmeasurable levels on native-like trimers. We are also able to classify the glycan processing states of all N-glycans present on the various constructs, thus extending our earlier site-specific analysis of the BG505 SOSIP.664 trimer (). Our findings emphasize how the glycan shield is influenced by the quaternary structure of the Env spike and highlight the relevance of native-like structures to Env vaccine development.



Glycosylation processing on monomeric, uncleaved, and cleaved Env proteins.

To thoroughly investigate the influence of trimerization- and cleavage-induced structural integrity on Env glycosylation, we used comparable conditions to express and purify monomeric gp120, native-like SOSIP.664 trimers, and uncleaved, nonnative WT.SEKS gp140 pseudotrimers, all based on the BG505 genotype. The design and characteristics of these proteins have been described previously (, , , ,). The WT.SEKS construct differs from SOSIP.664 in that it lacks the stabilizing SOSIP mutations and contains an inactivated furin cleavage site (RRRRRR mutated to SEKS); the resulting uncleaved pseudotrimers have a nonnative conformation (). The monomeric gp120 protein is isogenic with the gp120 subunit of the SOSIP.664 trimer. The designs of all three constructs are summarized in Fig. 1A. The three proteins were all produced in transiently transfected human embryonic kidney (HEK) 293F cells and purified using 2G12 affinity chromatography followed by size-exclusion chromatography (SEC).

Design and glycosylation patterns of BG505 gp120, WT.SEKS, and SOSIP.664. (A) Schematic representation of the BG505 gp120, WT.SEKS, and SOSIP.664 constructs. Changes to the wild-type BG505 sequence are highlighted in blue. (B) HILIC-UPLC profiles of the enzymatically released N-linked glycans of the three constructs, transiently produced in HEK 293F cells and purified by 2G12 affinity chromatography followed by SEC. Oligomannose-type and hybrid glycans (green) were identified by their sensitivity to endo H digestion. Peaks corresponding to complex-type glycans are shown in pink. The peaks were integrated, and the pie charts summarize the quantification of the peak areas. Glycan symbols are as shown in Fig. 2.

N-linked glycans were enzymatically released from all three constructs, fluorescently labeled, and analyzed by hydrophilic interaction chromatography-ultraperformance liquid chromatography (HILIC-UPLC) (Fig. 1B). Using endo-β-N-acetylglucosaminidase H (endo H) to digest the oligomannose-type glycans and by integration of the resulting chromatograms, oligomannose-type glycans were shown to account for 36% (gp120 monomers), 35% (WT.SEKS gp140), and 68% (SOSIP.664 trimers) of the total glycan populations. This outcome is consistent with a previous report that complex-type glycans are significantly more abundant on uncleaved pseudotrimers than on native-like trimers (). Although the analyses of the WT.SEKS and SOSIP.664 glycoproteins included contributions from the four glycans on gp41, the overall outcome was dominated by the 24 glycan sites on gp120. In summary, the total oligomannose contents of both the monomeric gp120 and uncleaved gp140 forms of BG505 Env are quite similar, with each protein having approximately half the oligomannose content of the native-like SOSIP.664 trimer.


Glycan databases reveal details of cell-directed glycan processing.

To facilitate the subsequent site-specific N-glycosylation analysis of the gp120, WT.SEKS, and SOSIP.664 glycoproteins and to probe their glycan structures in greater detail, we generated libraries of enzymatically released, unlabeled glycans by using ion mobility-electrospray ionization mass spectrometry (IM-ESI MS). The mobility-extracted singly charged glycans from the three glycoproteins are shown in Fig. 2. A significant population of oligomannose-type Man5–9GlcNAc2 glycans is present on all three glycoproteins and is most evident in the BG505 SOSIP.664 spectrum. This observation is consistent with the HILIC-UPLC data presented in Fig. 1. Ion mobility mass spectrometry using negative fragmentation mode allows the detailed assignment of isomeric glycan structures (). The number and type of glycan structures identified for the gp120, WT.SEKS, and SOSIP.664 proteins, with about 90 identified isobaric structures, are highly similar, although the abundances vary (see Table S1 in the supplemental material). Fine structural details of the diversity of complex-type glycans present on all three constructs were revealed. The extremes of glycan processing, including the presence of terminal fucoses, sulfates, GlcNAcs, and GalNAcs, are directed by the producer cell's glycosylation machinery. In contrast, the oligomannose-type glycans represent an intrinsic structural feature of Env ().

Ion mobility mass spectrometry analysis of BG505 Env glycoproteins. Mobility-extracted singly charged negative-ion electrospray spectra are shown for N-linked glycans found on the following BG505 Env proteins: gp120 monomers (A), WT.SEKS pseudotrimers (B), and SOSIP.664 trimers (C). The inset in panel B shows an example of a DriftScope image derived from gp120 monomers, with singly charged ions encircled with a yellow oval. The peaks of the oligomannose series Man5–9GlcNAc2 are highlighted in green. A list of identified glycans is given in Table S1 in the supplemental material.


Quantitative site-specific N-glycosylation analysis.

We performed a quantitative, site-specific N-glycosylation analysis using in-line liquid chromatography-ESI MS (LC-ESI MS) to thoroughly investigate how the formation of native-like, cleavage-induced trimers influences the glycan shield. We previously validated this method (). We used a panel of different proteases to create peptides and glycopeptides from the gp120, WT.SEKS, and SOSIP.664 proteins, enriched glycopeptide populations, and then quantified the relative abundances of individual glycans by assessing the ion intensities over all charge states. The quantified and summarized data for the three Env constructs show that the processing states of distinct N-glycosylation sites in the glycan shields of gp120 monomers and pseudotrimers are very similar to each other but also quite different from those for native-like SOSIP.664 trimers (Fig. 3).

Quantitative site-specific N-glycosylation of BG505 Env glycoproteins. Relative quantification is shown for the N-glycosylation sites on the gp120 subunit (A) and the gp41 subunit (B) of gp120 monomers (no gp41 present), WT.SEKS pseudotrimers, and SOSIP.664 trimers. The proteins were digested with trypsin, chymotrypsin, pronase, GluC, or GluC plus trypsin and then analyzed by LC-ESI MS. Quantifications are based on the peak lists given in Tables S2, S3, and S4 in the supplemental material. The percentages corresponding to this figure are shown in Table S5. Glycans are categorized as oligomannose series (M5 to M9; Man5GlcNAc2 to Man9GlcNAc2), hybrids (H), and fucosylated hybrids (FH), and also by the number of branching antennae (A) of complex-type glycans. An, number (n) of antennae; Gn, number (n) of galactose residues; F, presence of a core fucose (). The bar graphs represent the means for two analytical replicates, and the quantification of oligomannose-type (green) and complex/hybrid glycans (pink) on individual sites is summarized in the pie charts. The processing states of sites for which no quantitative analysis could be performed were classified by qualitative analysis of exoglycosidase-treated glycopeptides, as summarized by colored squares (Table S6).

In the present study, the site-specific glycosylation profile of SOSIP.664 trimers derived from transiently transfected HEK 293F cells is highly similar to previously published data on the same trimers produced in a stable HEK 293T cell line (). Quantitative site-specific glycan profiles of comparably expressed and purified BG505 gp120 and WT.SEKS gp140 proteins were not derived previously. Their availability now allows a comparison with SOSIP.664 trimers that reveals key aspects of how Env is glycosylated. In cases where quantitative site-specific data could not be obtained, the processing states of these sites could be classified broadly according to their susceptibility to sequential endo H and peptide-N-glycosidase F (PNGase F) digestions (Table S6). The resulting information is incorporated into Fig. 3, and the models are shown in Fig. 4. For reasons outlined in Materials and Methods, the endo H-plus-PNGase F digestion method is unsuitable for precisely quantifying the glycan compositions of specific sites, but it is sufficient for classifying glycans into broad processing states.

Models of a fully glycosylated BG505 gp120 monomer and a SOSIP.664 trimer. Models of the glycosylated gp120 monomer (A) and the glycosylated SOSIP.664 trimer (B) were derived from one previously described elsewhere (). The monomer is oriented as it would appear in situ as a subunit of the SOSIP.664 trimer. The glycans on the models are colored according to their oligomannose content, as derived in the present study. N-glycan sites for which quantitative results of sufficient quality could not be obtained were classified by qualitative analysis according to their susceptibility to endo H and PNGase F digestion (Table S6).

The site-specific analysis of BG505 gp120 revealed numerous positions where exclusively or almost exclusively oligomannose-type glycans are present. These sites define the gp120 IMP (). Note that the glycan repertoires are highly similar for the corresponding locations in the gp120 subunits of the uncleaved WT.SEKS pseudotrimer and the SOSIP.664 trimer (Fig. 3A). However, whereas Man9GlcNAc2 moieties dominate the sites forming the IMP on the SOSIP.664 trimer (e.g., N234, N363, N339, and N392) (Fig. 3A), there is additional but modest trimming of these sites toward smaller oligomannose glycans on the gp120 monomer and the pseudotrimer. Other sites on the gp120 monomer that contain a significant population of complex-type glycans are less processed on the native-like trimer (e.g., N137, N156, N160, N197, N276, and N355). The overall dominance of oligomannose-type glycosylation, however, is conserved among the three Env proteins, which supports the definition of the IMP as an intrinsic feature of the gp120 protein, whatever its quaternary context (). The N295 site seems to be protected comparably from glycan processing enzymes on all three constructs; it is the only site where the quaternary context and cleavage status do not increase glycan processing. The highly conserved “supersite of vulnerability” on the uncleaved WT.SEKS glycoprotein, i.e., N332, carries a small population of complex-type glycans, whereas this site is entirely oligomannose on both the cleaved SOSIP.664 trimer and the gp120 monomer. A likely explanation is that the conformationally heterogeneous pseudotrimers include a subpopulation on which processing enzymes can access and modify this antigenically important site at the heart of the IMP. The site-specific glycosylation states of the gp41 subunits of the BG505 WT.SEKS pseudotrimer and the BG505.664 trimer (Fig. 3B) are largely similar in that complex-type glycosylation dominates. However, the native-like trimer has an elevated population of oligomannose glycans at N625 and N637, indicating steric inaccessibility in those regions.

To display the site-specific glycosylation analysis and to facilitate structural interpretation, we mapped the distribution of the different glycan processing states across the BG505 gp120 monomer (Fig. 4A) and the SOSIP.664 trimer (Fig. 4B), using a model of a fully glycosylated trimer derived from a cryo-electron microscopy structure (, ). All the glycosylation sites are displayed, with the sites classified as mainly oligomannose, mainly complex, or mixed.


Formation of native-like trimers results in interprotomer control of glycan processing.

Based on the BG505 SOSIP.664 glycosylation map, we created two heat maps displaying the site-specific increase in oligomannose-type glycans on the structure of the cleaved trimer relative to the gp120 monomer (Fig. 5A) and the pseudotrimer (Fig. 5B). The cleavage-dependent formation of native-like trimers has a significant effect on the processing state of several glycans, including those at the trimer apex and the protomer interface. The increase in oligomannose-type glycans on the native trimer relative to the monomer or pseudotrimer can be viewed as a decrease in enzymatic processing consistent with the structural constraints that limit processing. For example, the glycan at N276 on SOSIP.664, near the CD4 binding site (CD4bs), has an ∼75% oligomannose content, whereas the corresponding value for the same site on the gp120 monomer is ∼5%; the glycan at N276 is the gp120 glycan that differs the most in this regard (Fig. 5A). Other glycans affected similarly but less profoundly are N156 (∼60% oligomannose on monomers versus 100% on trimers, hence a 40 percentage point (pp) increase in Fig. 4), N160 (∼60 pp increase), and N197 (∼50 pp increase); each of these sites is located at the trimer apex or protomer interface and thus is in a different quaternary context on the SOSIP.664 trimer compared to the gp120 monomer. Similarly, the outer domain N355 glycan is highly processed on monomeric gp120 but is a mixed glycan site (∼40 pp increase in oligomannose) on the SOSIP.664 trimer. In this case, the model suggests that the presence (trimer) or absence (monomer) of proximal gp41 glycans may be the key influence (Fig. 4A).

Heat maps on the surfaces of trimers, showing the increase in oligomannose glycans on BG505 SOSIP.664 trimers compared to gp120 monomers (A) and pseudotrimers (B). The increase in oligomannose content was calculated for sites for which quantitative data were available. To derive the heat map, a percentage point was calculated for each glycosylation site corresponding to an arithmetic difference of two percentage points; the percentage of oligomannose-type glycan for each of these sites on gp120 monomers or WT.SEKS pseudotrimers was subtracted from the corresponding percentage for SOSIP.664 trimers.

The formation of native-like trimers also has subtle influences on glycan trimming within the IMP. Thus, several IMP glycans are slightly less trimmed on the trimers, leading to an elevation in the abundance of Man9GlcNAc2 and an associated reduction in Man5–8GlcNAc2 (N234, N339, N363, N386, N392, and N448) and/or a slight decrease in complex-type glycans (N234, N262, and N363) (Fig. 3).


There is an additional mannose patch on native-like trimers but not pseudotrimers.

Broadly similar differences in glycan processing were also found when SOSIP.664 trimers were compared to the uncleaved, nonnative pseudotrimers (Fig. 4B). The differences were quantitatively smaller than those for comparison of gp120 monomers versus SOSIP.664 trimers, as is apparent from the color gradient of the heat map, but they were qualitatively similar (Fig. 5). Thus, there was an ∼35 pp increase in oligomannose for the N160 and N197 glycans at the apex of the native trimer compared to the pseudotrimer, whereas the corresponding increase for the N156 glycan was 20 pp. The biggest difference between the two proteins was seen for the N301 site, near the protomer interface; that glycan almost completely switched from highly processed on the pseudotrimer to oligomannose dominated on the SOSIP.664 trimer. We were not able to gain quantitative site-specific data for the N301 site on gp120 monomers, but the qualitative deglycosylation experiments did indicate that it had a mixed processing state (Table S6).

One notable glycan is the N262 glycan, which is known to play a critical role in gp120 folding (, ). While this site is exclusively dominated by oligomannose-type glycans on SOSIP.664, it has a mixed composition (∼50% complex glycans) on the pseudotrimer, although Man9GlcNAc2 still remains the most prominent oligomannose-type structure. One explanation may be that more than one folding state exists within the total population of pseudotrimers, for example, there may be a subpopulation in which aberrant disulfide bonds have formed (). The gp41 glycan that differs most between the SOSIP.664 trimer and the pseudotrimer is N637, which resides near the protomer interface, very close to N276. Thus, there is an increase of more than 30 pp for oligomannose at the N637 site on the native trimer compared to the pseudotrimer (Fig. 4B). The remaining gp120 glycans near the IMP and the other gp41 glycans differ only subtly between the SOSIP.664 trimer and the pseudotrimer, similar to what was seen for the gp120 monomer comparison described above.

Overall, the results show that a glycan patch with increased mannose content is uniquely present on the fully cleaved, native-like SOSIP.664 trimer. This trimer-associated mannose patch (TAMP) wraps around the trimer apex and the protomer interface and includes, at minimum, the N156, N160, N197, N262, N276, N301, and N637 glycans.


Trimer formation constrains processing at a fractionally occupied O-glycosylation site.

Recombinant Env glycoproteins have been reported to contain O-linked glycans at gp120 position T499 (, , , ). We searched the LC-ESI MS spectra of the deglycosylated tryptic digests of the three Env constructs for exact mass matches of O-glycosylated peptides. We then confirmed them by the presence of the characteristic oxonium ions as well as by using higher-energy collisional dissociation (HCD) fragmentation data. We were thereby able to identify microheterogeneity of commonly known O-glycans on T499 of each BG505 Env protein, mainly of the mono- and disialyl core 1 types, but with highly different fractional occupancies (Fig. 6; Table S7). We quantified the relative abundances of individual O-glycan structures in the same way as that for the N-linked glycans, by adding up the ion intensities over all charge states for the individual glycopeptides. By including the nonglycosylated peptide, which contains an unmodified threonine, we could determine the fractional occupancy of the T499 site.

O-glycosylation of recombinant Env glycoproteins. (A) The location of the T499 O-glycosylation site is highlighted in red on the BG505 SOSIP.664 trimer model. (B) Quantification of the O-glycans identified on the gp120, WT.SEKS, and SOSIP.664 Env proteins, based on the peak list shown in Table S7.

O-glycan occupancy of the T499 site was highest for monomeric gp120, at ∼7%, compared to ∼1% and ∼0.2% for the pseudotrimers and SOSIP.664 trimers, respectively (i.e., 7- to 35-fold reductions compared to the level for gp120). We therefore concluded that while T499 is indeed a potential site for O-glycosylation on gp120, it is only rarely occupied, and even less so on the pseudotrimer and the SOSIP.664 trimer. The T499 site is located close to the C terminus of gp120, so the nearby presence of gp41 may impose steric constraints on the glycosyltransferases. Furthermore, the structures of the native-like BG505 SOSIP.664 soluble trimer and the JR-FL membrane-associated trimer show that the T499 site is not surface exposed when gp41 is present (, , ). Indeed, in the native trimer context, the bulk of an O-glycan would not be accommodated within the gp120-gp41 interface, where T499 is located.


An effective B cell-based HIV-1 vaccine may need to elicit bNAbs. Rational vaccine design has led to the development and evaluation of many different potential Env immunogens (). An increasingly widespread opinion is that a native-like representation of Env where multiple bNAb epitopes are presented but nonneutralizing antibody epitopes are occluded is a highly relevant option (, ). As many bNAb epitopes include glycans, the integrity of the glycan shield is a key factor that needs to be considered in Env immunogen design. Glycan processing is not simply a function of the number of glycosylation sites on the Env protein backbone but is also related to the quaternary architecture of the native-like trimer (). Nonnative conformations of Env are reflected in their overall glycan profile, with pseudotrimers generally bearing a much higher content of processed glycans (). This observation applies to the uncleaved BG505 WT.SEKS pseudotrimers that serve as one point of comparison in the present study. These Env proteins, like others of the same basic design, adopt a variety of different shapes and conformations as observed by electron microscopy, contain aberrant, noncanonical disulfide bonds, and are atypically sensitive to proteases, and various of their trimer association domains are atypically accessible for hydrogen-deuterium exchange reactions (, , , , ). Consistent with their nonnative structure, the immunogenicity of BG505 WT.SEKS proteins in rabbits is markedly inferior to that of the corresponding SOSIP.664 trimers ().

In this study, we used quantitative site-specific N-glycosylation analysis of isogenic monomeric, cleaved, and uncleaved soluble Env glycoproteins to show that the formation of native-like trimers markedly affects the integrity of the glycan shield by providing additional protection from α-mannosidase processing. The trimer-induced mannose patch (TAMP) is a previously postulated concept for how the glycan shield is remodeled upon oligomerization (). We are now able to confirm its existence and to map its location on the trimer surface (Fig. 5). Furthermore, we show that the adoption of this characteristic glycosylation signature requires the formation of a compact, native-like trimer, not simply the presence of multiple gp120 subunits within the same Env protein. In other words, like gp120 monomers, pseudotrimers lack a TAMP. Both trimerization and protease cleavage need to occur early in the nascent Env glycoprotein's egress through the secretory pathway to provide steric protection of multiple oligomannose glycans from additional α-mannosidase processing ().

The BG505 WT.SEKS pseudotrimers carry subpopulations of complex-type glycans on N-glycosylation sites (N234, N262, N332, and N363) where underprocessed, oligomannose-type Man8–9GlcNAc2 structures predominate on the native-like SOSIP.664 trimers. The presence of molecules with processing at these sites within the pseudotrimer preparation is consistent with nonnative folding and the impact of any aberrantly formed disulfide bonds. The heat maps in Fig. 5 show how the structural constraints that apply to the native trimer lead to an increase in oligomannose content. A converse perspective is that the loss of those constraints increases the processing of multiple glycans on the gp120 monomers and pseudotrimers. The outcome is generally an increase in the trimming of oligomannose-type glycans toward smaller forms and in the population of complex-type glycans (e.g., N355).

The detailed site-specific N-glycosylation profiles help us to understand how different Env immunogen designs drive differences in the processing of key glycans. For example, the gp120 monomers and WT.SEKS pseudotrimers bind the trimer-reactive, apex-recognizing bNAbs PG16 and PGT145 poorly or not at all (, ). The inability of the nonnative Env proteins to present these conformationally sensitive epitopes is also reflected in their aberrant profiles for the glycan sites near the trimer apex. For example, the N160 site on the native-like trimer is dominated by oligomannose-type glycans, whereas bi-, tri-, and tetra-antennary complex-type glycans predominate on the pseudotrimer. We also noted that the oligomannose content of the N276 glycan on the SOSIP.664 trimer is ∼70 pp higher than that at the same site on the gp120 monomer. Indeed, N276 was the gp120 glycan that differed the most between the trimer and the monomer in this regard. The N276 site was also more processed on the pseudotrimer than on the native-like trimer (35 pp lower oligomannose content). The N276 glycan is located near the CD4bs, where it plays a role in shielding key epitopes for bNAbs of the VRC01 class (). An oligomannose-type glycan at this position forms part of the epitope of the CAP257-RH1 antibody, which was isolated from a donor infected with a clade C HIV-1 strain (). The high-oligomannose status of the N276 glycan on native-like SOSIP.664 trimers may therefore reflect the composition of the same glycan on virion-associated Env (i.e., in the CAP257-RH1 donor). Inducing VRC01 class bNAbs is the goal of several Env vaccine programs based on targeting specific precursors of these antibodies in the human germ line repertoire followed by a boosting regimen intended to drive the maturation of any initially induced precursors. These programs use a variety of Env proteins, including those based on gp120 outer domains, gp120 monomers, or nonnative gp140s (,). The glycoform compositions of these immunogens will need to be determined experimentally, but some sites (including N276, when present) may be processed more highly than those on native trimers, based on what we have seen with the BG505 gp120 monomers and uncleaved pseudotrimers. The implications for the design of germ line-targeting priming and boosting immunogens would need to be considered.

In summary, site-specific glycan composition data such as those we describe here should be valuable guides to the design and use of Env immunogens intended to induce bNAbs against virion-associated epitopes that either contain or are influenced by glycans of defined compositions.



Expression and purification of Env proteins.

The design of the BG505 SOSIP.644 and WT.SEKS constructs has been described elsewhere (, ). The BG505 gp120 monomer sequence was identical to that of the gp120 subunit of the SOSIP.664 trimer, including the T332N and A501C mutations. Each env gene was transiently expressed in human embryonic kidney (HEK) 293F cells by using the pPPI4 vector system as described elsewhere (, ). A furin expression plasmid was cotransfected with the SOSIP.664 construct to increase trimer cleavage efficiency (, ). Env proteins were isolated from culture supernatants by 2G12 affinity chromatography followed by size-exclusion chromatography (SEC), as described previously (, ).


Analysis of total glycan profiles by HILIC-UPLC.

N-linked glycans were enzymatically released from Env proteins by in-gel digestion with peptide-N-glycosidase F (PNGase F) and subsequently fluorescently labeled with 2-aminobenzoic acid (2-AA), as previously described (, ). The 2-AA-labeled glycans were subsequently analyzed by hydrophilic interaction chromatography-ultraperformance liquid chromatography (HILIC-UPLC) in a Waters Acquity UPLC instrument (). The abundance of oligomannose-type glycans was assessed by digesting the released glycans with endo H (New England BioLabs) ().


Site-specific N-glycosylation analysis.

Ion mobility MS using a Waters Synapt G2Si mass spectrometer was used to analyze the total pool of PNGase F-released glycans from the Env glycoproteins, as described previously (). The results were used to create sample-specific glycan libraries for the subsequent site-specific N-glycosylation analyses. Env proteins (100 to 150 μg) were denatured and alkylated as described previously (). The following proteases or combinations of proteases were used for digestion at a 1:30 (wt/wt) ratio for 12 h at 37°C, according to the manufacturers' instructions: trypsin, chymotrypsin, GluC (all mass spectrometry grade; Promega), and pronase (Sigma-Aldrich). We also performed a sequential digestion using GluC (4 h, 37°C) and then trypsin (12 h, 37°C). Protease-digested samples were enriched for glycopeptides by use of a ProteoExtract glycopeptide enrichment kit (Merck Millipore).

Additionally, deglycosylated Env samples were prepared by digestion of tryptic and chymotryptic (non-glycopeptide-enriched) peptides with endo H (4 h, 37°C), followed by digestion with PNGase F (4 h, 37°C), according to the manufacturer's instructions. The processing state of the glycan site was then classified according to its susceptibility to endo H and PNGase F. The basis of this assignment method is that endo H cleaves oligomannose-type and hybrid glycans but leaves a single GlcNAc moiety that is not removed by the subsequent PNGase F digestion (leads to deamidation at sites with complex-type glycans). Unoccupied PNGSs remain as unmodified asparagines. Deamidation of asparagines can also occur spontaneously as a nonenzymatic reaction in proteins and peptides (), making this method unsuitable for exact quantifications. The information gained by this type of analysis is, however, sufficient for glycan classification into broad processing states.

All samples were analyzed by liquid chromatography-electrospray ionization mass spectrometry (LC-ESI MS) on a Q-Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific), as described previously (). Data interpretation and quantification were performed using Byonic and Byologic software ().


Site-specific O-glycosylation analysis.

We assessed O-glycosylation by using Byonic and Byologic software to analyze LC-ESI MS spectra derived from tryptic-digested, deglycosylated Env proteins, searching for the most common human O-glycans. Any exact mass matches of O-glycosylated peptides were manually confirmed by seeking the characteristic oxonium ions, as well as peptide fragmentation ions, among the HCD fragmentation data. The relative abundances of individual O-glycoforms and the corresponding unmodified peptide were determined by summing the intensities of the extracted-ion chromatograms (XICs) over all charge states, as follows: relative abundance = intensity of one glycoform/intensities of all glycoforms identified on the same peptide.


Supplemental material:


We thank Raymond A. Dwek for his support and Rogier Sanders for critically reading the manuscript.

A.-J.B. is the recipient of the Chris Scanlan Memorial Scholarship from Corpus Christi College, Oxford, United Kingdom. M.C. is supported by Scripps CHAVI-ID (grant 1UM1AI100663) and by an International AIDS Vaccine Initiative Neutralizing Antibody Center CAVD grant (glycan characterization and outer domain glycoform design). J.P.M. is supported by NIH HIVRAD grant P01 AI110657. N.Z. and A.K. were funded by Unither Virology.



Supplemental material for this article may be found at



1. Lasky LA, Groopman JE, Fennie CW, Benz PM, Capon DJ, Dowbenko DJ, Nakamura GR, Nunes WM, Renz ME, Berman PW. 1986. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 233:209–212. doi:10.1126/science.3014647. [PubMed] [CrossRef] []
2. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705–711. doi:10.1038/31514. [PubMed] [CrossRef] []
3. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307–312. doi:10.1038/nature01470. [PubMed] [CrossRef] []
4. Moore JP, Sodroski J. 1996. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 70:1863–1872. [PMC free article] [PubMed] []
5. Zhang M, Gaschen B, Blay W, Foley B, Haigwood N, Kuiken C, Korber B. 2004. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14:1229–1246. doi:10.1093/glycob/cwh106. [PubMed] [CrossRef] []
6. Travers SA. 2012. Conservation, compensation, and evolution of N-linked glycans in the HIV-1 group M subtypes and circulating recombinant forms. ISRN AIDS 2012:823605. doi:10.5402/2012/823605. [PMC free article] [PubMed] [CrossRef] []
7. Bonomelli C, Doores KJ, Dunlop DC, Thaney V, Dwek Ra Burton DR, Crispin M, Scanlan CN. 2011. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One 6:e23521. doi:10.1371/journal.pone.0023521. [PMC free article] [PubMed] [CrossRef] []
8. Doores KJ, Bonomelli C, Harvey DJ, Vasiljevic S, Dwek RA, Burton DR, Crispin M, Scanlan CN. 2010. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A 107:13800–13805. doi:10.1073/pnas.1006498107. [PMC free article] [PubMed] [CrossRef] []
9. Panico M, Bouche L, Binet D, O'Connor MJ, Rahman D, Pang PC, Canis K, North SJ, Desrosiers RC, Chertova E, Keele BF, Bess JW Jr, Lifson JD, Haslam SM, Dell A, Morris HR. 2016. Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding. Sci Rep 6:32956. doi:10.1038/srep32956. [PMC free article] [PubMed] [CrossRef] []
10. Pritchard LK, Harvey DJ, Bonomelli C, Crispin M, Doores KJ. 2015. Cell- and protein-directed glycosylation of native cleaved HIV-1 envelope. J Virol 89:8932–8944. doi:10.1128/JVI.01190-15. [PMC free article] [PubMed] [CrossRef] []
11. Pritchard LK, Spencer DI, Royle L, Bonomelli C, Seabright GE, Behrens AJ, Kulp DW, Menis S, Krumm SA, Dunlop DC, Crispin DJ, Bowden TA, Scanlan CN, Ward AB, Schief WR, Doores KJ, Crispin M. 2015. Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. Nat Commun 6:7479. doi:10.1038/ncomms8479. [PMC free article] [PubMed] [CrossRef] []
12. Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, de la Pena AT, Cupo A, Julien JP, van Gils M, Lee PS, Peng W, Paulson JC, Poignard P, Burton DR, Moore JP, Sanders RW, Wilson IA, Ward AB. 2014. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 40:669–680. doi:10.1016/j.immuni.2014.04.008. [PMC free article] [PubMed] [CrossRef] []
13. Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, Ramirez A, Derking R, van Gils MJ, Liang C-H, McBride R, von Bredow B, Shivatare SS, Wu C-Y, Chan-Hui P-Y, Liu Y, Feizi T, Zwick MB, Koff WC, Seaman MS, Swiderek K, Moore JP, Evans D, Paulson JC, Wong C-H, Ward AB, Wilson IA, Sanders RW, Poignard P, Burton DR. 2014. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 40:657–668. doi:10.1016/j.immuni.2014.04.009. [PMC free article] [PubMed] [CrossRef] []
14. Garces F, Sok D, Kong L, McBride R, Kim HJ, Saye-Francisco KF, Julien J-P, Hua Y, Cupo A, Moore JP, Paulson JC, Ward AB, Burton DR, Wilson IA. 2014. Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell 159:69–79. doi:10.1016/j.cell.2014.09.009. [PMC free article] [PubMed] [CrossRef] []
15. Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, Liu Y, Marozsan A, Cupo A, Klasse PJ, Hoffenberg S, Caulfield M, King CR, Hua Y, Le KM, Khayat R, Deller MC, Clayton T, Tien H, Feizi T, Sanders RW, Paulson JC, Moore JP, Stanfield RL, Burton DR, Ward AB, Wilson IA. 2013. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol 20:796–803. doi:10.1038/nsmb.2594. [PMC free article] [PubMed] [CrossRef] []
16. McLellan JS, Pancera M, Carrico C, Gorman J, Julien J-P, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul-Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang G-Y, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang Z-Y, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang L-X, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336–343. doi:10.1038/nature10696. [PMC free article] [PubMed] [CrossRef] []
17. Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, Scheid JF, Halper-Stromberg A, Gnanapragasam PNP, Spencer DIR, Seaman MS, Schuitemaker H, Feizi T, Nussenzweig MC, Bjorkman PJ. 2012. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A 109:E3268–E3277. doi:10.1073/pnas.1217207109. [PMC free article] [PubMed] [CrossRef] []
18. Pancera M, Shahzad-Ul-Hussan S, Doria-Rose NA, McLellan JS, Bailer RT, Dai K, Loesgen S, Louder MK, Staupe RP, Yang Y, Zhang B, Parks R, Eudailey J, Lloyd KE, Blinn J, Alam SM, Haynes BF, Amin MN, Wang L-X, Burton DR, Koff WC, Nabel GJ, Mascola JR, Bewley CA, Kwong PD. 2013. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol 20:804–813. doi:10.1038/nsmb.2600. [PMC free article] [PubMed] [CrossRef] []
19. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang P-S, Wang S-K, Stanfield RL, Julien J-P, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong C-H, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334:1097–1103. doi:10.1126/science.1213256. [PMC free article] [PubMed] [CrossRef] []
20. Scharf L, Scheid JF, Lee JH, West AP, Chen C, Gao H, Gnanapragasam PNP, Mares R, Seaman MS, Ward AB, Nussenzweig MC, Bjorkman PJ. 2014. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep 7:785–795. doi:10.1016/j.celrep.2014.04.001. [PMC free article] [PubMed] [CrossRef] []
21. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien J-P, Wang S-K, Ramos A, Chan-Hui P-Y, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong C-H, Phogat S, Wrin T, Simek MD, Koff WC, Wilson IA, Burton DR, Poignard P. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466–470. doi:10.1038/nature10373. [PMC free article] [PubMed] [CrossRef] []
22. Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, Georgiev IS, Chuang G-Y, Druz A, Doria-Rose NA, Laub L, Sliepen K, van Gils MJ, de la Peña AT, Derking R, Klasse P-J, Migueles SA, Bailer RT, Alam M, Pugach P, Haynes BF, Wyatt RT, Sanders RW, Binley JM, Ward AB, Mascola JR, Kwong PD, Connors M. 2014. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515:138–142. doi:10.1038/nature13601. [PMC free article] [PubMed] [CrossRef] []
23. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR. 2002. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1→2 mannose residues on the outer face of gp120. J Virol 76:7306–7321. doi:10.1128/JVI.76.14.7306-7321.2002. [PMC free article] [PubMed] [CrossRef] []
24. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA. 2003. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300:2065–2071. doi:10.1126/science.1083182. [PubMed] [CrossRef] []
25. Freund NT, Horwitz JA, Nogueira L, Sievers SA, Scharf L, Scheid JF, Gazumyan A, Liu C, Velinzon K, Goldenthal A, Sanders RW, Moore JP, Bjorkman PJ, Seaman MS, Walker BD, Klein F, Nussenzweig MC. 2015. A new glycan-dependent CD4-binding site neutralizing antibody exerts pressure on HIV-1 in vivo. PLoS Pathog 11:e1005238. doi:10.1371/journal.ppat.1005238. [PMC free article] [PubMed] [CrossRef] []
26. Vollenweider F, Benjannet S, Decroly E, Savaria D, Lazure C, Thomas G, Chretien M, Seidah NG. 1996. Comparative cellular processing of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp160 by the mammalian subtilisin/kexin-like convertases. Biochem J 314:521–532. doi:10.1042/bj3140521. [PMC free article] [PubMed] [CrossRef] []
27. Moulard M, Decroly E. 2000. Maturation of HIV envelope glycoprotein precursors by cellular endoproteases. Biochim Biophys Acta 1469:121–132. doi:10.1016/S0304-4157(00)00014-9. [PubMed] [CrossRef] []
28. Decroly E, Wouters S, Di Bello C, Lazure C, Ruysschaert JM, Seidah NG. 1996. Identification of the paired basic convertases implicated in HIV gp160 processing based on in vitro assays and expression in CD4(+) cell lines. J Biol Chem 271:30442–30450. doi:10.1074/jbc.271.48.30442. [PubMed] [CrossRef] []
29. Decroly E, Vandenbranden M, Ruysschaert JM, Cogniaux J, Jacob GS, Howard SC, Marshall G, Kompelli A, Basak A, Jean F, Lazure C, Benjannet S, Chretien M, Day R, Seidah NG. 1994. The convertases furin and PC1 can both cleave the human immunodeficiency virus (HIV)-1 envelope glycoprotein gp160 into gp120 (HIV-I SU) and gp41 (HIV-I TM). J Biol Chem 269:12240–12247. [PubMed] []
30. Franzusoff A, Volpe AM, Josse D, Pichuantes S, Wolf JR. 1995. Biochemical and genetic definition of the cellular protease required for HIV-1 gp160 processing. J Biol Chem 270:3154–3159. doi:10.1074/jbc.270.7.3154. [PubMed] [CrossRef] []
31. Hallenberger S, Bosch V, Angliker H, Shaw E, Klenk HD, Garten W. 1992. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 360:358–361. doi:10.1038/360358a0. [PubMed] [CrossRef] []
32. Thomas G. 2002. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 3:753–766. doi:10.1038/nrm934. [PMC free article] [PubMed] [CrossRef] []
33. Bass J, Turck C, Rouard M, Steiner DF. 2000. Furin-mediated processing in the early secretory pathway: sequential cleavage and degradation of misfolded insulin receptors. Proc Natl Acad Sci U S A 97:11905–11909. doi:10.1073/pnas.97.22.11905. [PMC free article] [PubMed] [CrossRef] []
34. Binley JM, Sanders RW, Master A, Cayanan CS, Wiley CL, Schiffner L, Travis B, Kuhmann S, Burton DR, Hu SL, Olson WC, Moore JP. 2002. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 76:2606–2616. doi:10.1128/JVI.76.6.2606-2616.2002. [PMC free article] [PubMed] [CrossRef] []
35. Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Pena AT, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, van Gils MJ, King CR, Wilson IA, Ward AB, Klasse PJ, Moore JP. 2013. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 9:e1003618. doi:10.1371/journal.ppat.1003618. [PMC free article] [PubMed] [CrossRef] []
36. Ringe RP, Sanders RW, Yasmeen A, Kim HJ, Lee JH, Cupo A, Korzun J, Derking R, van Montfort T, Julien J-P, Wilson IA, Klasse PJ, Ward AB, Moore JP. 2013. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A 110:18256–18261. doi:10.1073/pnas.1314351110. [PMC free article] [PubMed] [CrossRef] []
37. Yasmeen A, Ringe R, Derking R, Cupo A, Julien JP, Burton DR, Ward AB, Wilson IA, Sanders RW, Moore JP, Klasse PJ. 2014. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology 11:41. doi:10.1186/1742-4690-11-41. [PMC free article] [PubMed] [CrossRef] []
38. Georgiev IS, Joyce MG, Yang Y, Sastry M, Zhang B, Baxa U, Chen RE, Druz A, Lees CR, Narpala S, Schon A, Van Galen J, Chuang GY, Gorman J, Harned A, Pancera M, Stewart-Jones GB, Cheng C, Freire E, McDermott AB, Mascola JR, Kwong PD. 2015. Single-chain soluble BG505.SOSIP gp140 trimers as structural and antigenic mimics of mature closed HIV-1 Env. J Virol 89:5318–5329. doi:10.1128/JVI.03451-14. [PMC free article] [PubMed] [CrossRef] []
39. Ringe RP, Yasmeen A, Ozorowski G, Go EP, Pritchard LK, Guttman M, Ketas TA, Cottrell CA, Wilson IA, Sanders RW, Cupo A, Crispin M, Lee KK, Desaire H, Ward AB, Klasse PJ, Moore JP. 2015. Influences on the design and purification of soluble, recombinant native-like HIV-1 envelope glycoprotein trimers. J Virol 89:12189–12210. doi:10.1128/JVI.01768-15. [PMC free article] [PubMed] [CrossRef] []
40. Pritchard LK, Vasiljevic S, Ozorowski G, Seabright GE, Cupo A, Ringe R, Kim HJ, Sanders RW, Doores KJ, Burton DR, Wilson IA, Ward AB, Moore JP, Crispin M. 2015. Structural constraints determine the glycosylation of HIV-1 envelope trimers. Cell Rep 11:1604–1613. doi:10.1016/j.celrep.2015.05.017. [PMC free article] [PubMed] [CrossRef] []
41. Zhu X, Borchers C, Bienstock RJ, Tomer KB. 2000. Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39:11194–11204. doi:10.1021/bi000432m. [PubMed] [CrossRef] []
42. Go EP, Liao H-X, Alam SM, Hua D, Haynes BF, Desaire H. 2013. Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins. J Proteome Res 12:1223–1234. doi:10.1021/pr300870t. [PMC free article] [PubMed] [CrossRef] []
43. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ. 1990. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 265:10373–10382. [PubMed] []
44. Walker LM, Phogat SK, Chan-Hui P-Y, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285–289. doi:10.1126/science.1178746. [PMC free article] [PubMed] [CrossRef] []
45. Pritchard LK, Spencer DI, Royle L, Vasiljevic S, Krumm SA, Doores KJ, Crispin M. 2015. Glycan microheterogeneity at the PGT135 antibody recognition site on HIV-1 gp120 reveals a molecular mechanism for neutralization resistance. J Virol 89:6952–6959. doi:10.1128/JVI.00230-15. [PMC free article] [PubMed] [CrossRef] []
46. Doores KJ, Kong L, Krumm SA, Le KM, Sok D, Laserson U, Garces F, Poignard P, Wilson IA, Burton DR. 2015. Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope. J Virol 89:1105–1118. doi:10.1128/JVI.02905-14. [PMC free article] [PubMed] [CrossRef] []
47. Doores KJ. 2015. The HIV glycan shield as a target for broadly neutralizing antibodies. FEBS J 282:4679–4691. doi:10.1111/febs.13530. [PMC free article] [PubMed] [CrossRef] []
48. Alexandre KB, Gray ES, Lambson BE, Moore PL, Choge IA, Mlisana K, Karim SS, McMahon J, O'Keefe B, Chikwamba R, Morris L. 2010. Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, griffithsin, cyanovirin-N and scytovirin. Virology 402:187–196. doi:10.1016/j.virol.2010.03.021. [PMC free article] [PubMed] [CrossRef] []
49. Coss KP, Vasiljevic S, Pritchard LK, Krumm SA, Glaze M, Madzorera S, Moore PL, Crispin M, Doores KJ. 5 October 2016. HIV-1 glycan density drives the persistence of the mannose patch within an infected individual. J Virol 10.1128/jvi.01542-16. [PMC free article] [PubMed] [CrossRef] []
50. Behrens A-J, Vasiljevic S, Pritchard LK, Harvey DJ, Andev RS, Krumm SA, Struwe WB, Cupo A, Kumar A, Zitzmann N, Seabright GE, Kramer HB, Spencer DI, Royle L, Lee JH, Klasse PJ, Burton DR, Wilson IA, Ward AB, Sanders RW, Moore JP, Doores KJ, Crispin M. 2016. Composition and antigenic effects of individual glycan sites of a trimeric HIV-1 envelope glycoprotein. Cell Rep 14:2695–2706. doi:10.1016/j.celrep.2016.02.058. [PMC free article] [PubMed] [CrossRef] []
51. Go EP, Herschhorn A, Gu C, Castillo-Menendez L, Zhang S, Mao Y, Chen H, Ding H, Wakefield JK, Hua D, Liao HX, Kappes JC, Sodroski J, Desaire H. 2015. Comparative analysis of the glycosylation profiles of membrane-anchored HIV-1 envelope glycoprotein trimers and soluble gp140. J Virol 89:8245–8257. doi:10.1128/JVI.00628-15. [PMC free article] [PubMed] [CrossRef] []
52. Crispin M, Doores KJ. 2015. Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design. Curr Opin Virol 11:63–69. doi:10.1016/j.coviro.2015.02.002. [PMC free article] [PubMed] [CrossRef] []
53. Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L, Arendt H, Kim HJ, Lee JH, Pugach P, Williams M, Debnath G, Moldt B, van Breemen MJ, Isik G, Medina-Ramirez M, Back JW, Koff WC, Julien JP, Rakasz EG, Seaman MS, Guttman M, Lee KK, Klasse PJ, LaBranche C, Schief WR, Wilson IA, Overbaugh J, Burton DR, Ward AB, Montefiori DC, Dean H, Moore JP. 2015. HIV-1 vaccines. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 349:aac4223. doi:10.1126/science.aac4223. [PMC free article] [PubMed] [CrossRef] []
54. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA. 2013. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342:1477–1483. doi:10.1126/science.1245625. [PMC free article] [PubMed] [CrossRef] []
55. Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, Burton DR, Sanders RW, Moore JP, Carragher B, Wilson IA, Ward AB. 2013. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342:1484–1490. doi:10.1126/science.1245627. [PMC free article] [PubMed] [CrossRef] []
56. Binley JM, Sanders RW, Clas B, Schuelke N, Master A, Guo Y, Kajumo F, Anselma DJ, Maddon PJ, Olson WC, Moore JP. 2000. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 74:627–643. doi:10.1128/JVI.74.2.627-643.2000. [PMC free article] [PubMed] [CrossRef] []
57. Khayat R, Lee JH, Julien J-P, Cupo A, Klasse PJ, Sanders RW, Moore JP, Wilson IA, Ward AB. 2013. Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. J Virol 87:9865–9872. doi:10.1128/JVI.01222-13. [PMC free article] [PubMed] [CrossRef] []
58. Klasse PJ, Depetris RS, Pejchal R, Julien J-P, Khayat R, Lee JH, Marozsan AJ, Cupo A, Cocco N, Korzun J, Yasmeen A, Ward AB, Wilson IA, Sanders RW, Moore JP. 2013. Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. J Virol 87:9873–9885. doi:10.1128/JVI.01226-13. [PMC free article] [PubMed] [CrossRef] []
59. Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, Kalyanaraman R, Paluch M, Berkhout B, Maddon PJ, Olson WC, Lu M, Moore JP. 2002. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 76:8875–8889. doi:10.1128/JVI.76.17.8875-8889.2002. [PMC free article] [PubMed] [CrossRef] []
60. Harvey DJ, Sobott F, Crispin M, Wrobel A, Bonomelli C, Vasiljevic S, Scanlan CN, Scarff CA, Thalassinos K, Scrivens JH. 2011. Ion mobility mass spectrometry for extracting spectra of N-glycans directly from incubation mixtures following glycan release: application to glycans from engineered glycoforms of intact, folded HIV gp120. J Am Soc Mass Spectrom 22:568–581. doi:10.1007/s13361-010-0053-0. [PubMed] [CrossRef] []
61. Lee JH, de Val N, Lyumkis D, Ward AB. 2015. Model building and refinement of a natively glycosylated HIV-1 Env protein by high-resolution cryoelectron microscopy. Structure 23:1943–1951. doi:10.1016/j.str.2015.07.020. [PMC free article] [PubMed] [CrossRef] []
62. Mathys L, Francois KO, Quandte M, Braakman I, Balzarini J. 2014. Deletion of the highly conserved N-glycan at Asn260 of HIV-1 gp120 affects folding and lysosomal degradation of gp120, and results in loss of viral infectivity. PLoS One 9:e101181. doi:10.1371/journal.pone.0101181. [PMC free article] [PubMed] [CrossRef] []
63. Moore JP, Willey RL, Lewis GK, Robinson J, Sodroski J. 1994. Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1. J Virol 68:6836–6847. [PMC free article] [PubMed] []
64. Go EP, Cupo A, Ringe R, Pugach P, Moore JP, Desaire H. 2015. Native conformation and canonical disulfide bond formation are interlinked properties of HIV-1 Env glycoproteins. J Virol 90:2884–2894. doi:10.1128/JVI.01953-15. [PMC free article] [PubMed] [CrossRef] []
65. Go EP, Hua D, Desaire H. 2014. Glycosylation and disulfide bond analysis of transiently and stably expressed clade C HIV-1 gp140 trimers in 293T cells identifies disulfide heterogeneity present in both proteins and differences in O-linked glycosylation. J Proteome Res 13:4012–4027. doi:10.1021/pr5003643. [PMC free article] [PubMed] [CrossRef] []
66. Stansell E, Panico M, Canis K, Pang PC, Bouche L, Binet D, O'Connor MJ, Chertova E, Bess J, Lifson JD, Haslam SM, Morris HR, Desrosiers RC, Dell A. 2015. gp120 on HIV-1 virions lacks O-linked carbohydrate. PLoS One 10:e0124784. doi:10.1371/journal.pone.0124784. [PMC free article] [PubMed] [CrossRef] []
67. Lee JH, Ozorowski G, Ward AB. 2016. Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 351:1043–1048. doi:10.1126/science.aad2450. [PMC free article] [PubMed] [CrossRef] []
68. Sliepen K, Sanders RW. 2016. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies. Expert Rev Vaccines 15:349–365. doi:10.1586/14760584.2016.1129905. [PubMed] [CrossRef] []
69. de Taeye SW, Ozorowski G, Torrents de la Pena A, Guttman M, Julien JP, van den Kerkhof TL, Burger JA, Pritchard LK, Pugach P, Yasmeen A, Crampton J, Hu J, Bontjer I, Torres JL, Arendt H, DeStefano J, Koff WC, Schuitemaker H, Eggink D, Berkhout B, Dean H, LaBranche C, Crotty S, Crispin M, Montefiori DC, Klasse PJ, Lee KK, Moore JP, Wilson IA, Ward AB, Sanders RW. 2015. Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. Cell 163:1702–1715. doi:10.1016/j.cell.2015.11.056. [PMC free article] [PubMed] [CrossRef] []
70. Sanders RW, Moore JP. Native-like Env trimers as a platform for HIV-1 vaccine design. Immunol Rev, in press. [PMC free article] [PubMed] []
71. Guttman M, Lee KK. 2013. A functional interaction between gp41 and gp120 is observed for monomeric but not oligomeric, uncleaved HIV-1 Env gp140. J Virol 87:11462–11475. doi:10.1128/JVI.01681-13. [PMC free article] [PubMed] [CrossRef] []
72. Lynch RM, Wong P, Tran L, O'Dell S, Nason MC, Li Y, Wu X, Mascola JR. 2015. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. J Virol 89:4201–4213. doi:10.1128/JVI.03608-14. [PMC free article] [PubMed] [CrossRef] []
73. Wibmer CK, Gorman J, Anthony CS, Mkhize NN, Druz A, York T, Schmidt SD, Labuschagne P, Louder MK, Bailer RT, Abdool Karim SS, Mascola JR, Williamson C, Moore PL, Kwong PD, Morris L. 2016. Structure of an N276-dependent HIV-1 neutralizing antibody targeting a rare V5 glycan hole adjacent to the CD4 binding site. J Virol 90:10220–10235. doi:10.1128/JVI.01357-16. [PMC free article] [PubMed] [CrossRef] []
74. McGuire AT, Gray MD, Dosenovic P, Gitlin AD, Freund NT, Petersen J, Correnti C, Johnsen W, Kegel R, Stuart AB, Glenn J, Seaman MS, Schief WR, Strong RK, Nussenzweig MC, Stamatatos L. 2016. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nat Commun 7:10618. doi:10.1038/ncomms10618. [PMC free article] [PubMed] [CrossRef] []
75. Jardine JG, Kulp DW, Havenar-Daughton C, Sarkar A, Briney B, Sok D, Sesterhenn F, Ereno-Orbea J, Kalyuzhniy O, Deresa I, Hu X, Spencer S, Jones M, Georgeson E, Adachi Y, Kubitz M, deCamp AC, Julien JP, Wilson IA, Burton DR, Crotty S, Schief WR. 2016. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351:1458–1463. doi:10.1126/science.aad9195. [PMC free article] [PubMed] [CrossRef] []
76. Scharf L, West AP, Sievers SA, Chen C, Jiang S, Gao H, Gray MD, McGuire AT, Scheid JF, Nussenzweig MC, Stamatatos L, Bjorkman PJ. 2016. Structural basis for germline antibody recognition of HIV-1 immunogens. eLife 5:e13783. doi:10.7554/eLife.13783. [PMC free article] [PubMed] [CrossRef] []
77. Julien J-P, Lee JH, Cupo A, Murin CD, Derking R, Hoffenberg S, Caulfield MJ, King CR, Marozsan AJ, Klasse PJ, Sanders RW, Moore JP, Wilson IA, Ward AB. 2013. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A 110:4351–4356. doi:10.1073/pnas.1217537110. [PMC free article] [PubMed] [CrossRef] []
78. Neville DC, Dwek RA, Butters TD. 2009. Development of a single column method for the separation of lipid- and protein-derived oligosaccharides. J Proteome Res 8:681–687. doi:10.1021/pr800704t. [PubMed] [CrossRef] []
79. Geiger T, Clarke S. 1987. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem 262:785–794. [PubMed] []

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)
Jawahar Raina

Leave a comment

Please note: comments must be approved before they are published.